DEBATE: Sequencing Small Molecules Is the Way ... - CLL Support
DEBATE: Sequencing Small Molecules Is the Way to Go, by Dr. Jennifer R.Brown at the Society of Hematologic Oncology 2022 Annual Meeting
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Unmutated patients on venetoclax?
In it, she refers to the trial where patients on venetoclax + obinutuzumab had much better results...
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista
ASH 2019 - Maturing CLL clinical trial data
Dr. Nicole Lamanna, Associate Clinical Professor of...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
with patients who received obinutuzumab plus chlorambucil: 88% vs. 64%. Overall response rates also...
CALQUENCE gets FDA approval for treating CLL
approval for Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor, was granted under...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
dose-escalation trial, the regimen led to a high rate of undetectable minimal residual disease...
Ibrutinib Slow but steady foreward movement.
Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)
Potential cure for CLL
AbbVie Pharm--positive phase 3 for CLL!
